EUVIMEDEUVIMED entdecken
Crossref

Urinary exosomal FAM153C-RPL19 chimeric RNA as a diagnostic and prognostic biomarker for prostate cancer in Chinese patients

Bisheng Cheng, Tianlong Luo, Yongxin Wu, Jintao Hu, Chenwei Yang, Jilin Wu, Yong Luo, WenTai Shangguan, Weijia Li, Lin Yang, Wenxue Huang, Cunzhen Ma und 6 weitere

Cancer Letters · 2025

DOI: 10.1016/j.canlet.2025.217938 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Bisheng Cheng und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China; Department of Urology, Nanfang Hospital, Sout…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Biomarkers, Tumor, Exosomes. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Special Project for Research and Development in Key areas of Guangdong Province, National Natural Science Foundation of China, Southern Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer (PCa) is one of the most common malignancies in men, with an increasing incidence worldwide. Early detection is crucial for improving patient outcomes, yet the current biomarker, prostate-specific antigen (PSA), lacks sufficient specificity and sensitivity, especially in the diagnostic gray zone (PSA 4-10 ng/mL). Novel noninvasive biomarkers are needed to enhance diagnostic accuracy and reduce unnecessary biopsies. This study analyzed prostate cancer tissue, plasma, and urine samples from multiple cohorts, including the Chinese Prostate Cancer Genome Epigenome Atlas (CPGEA) dataset and external validation cohorts. RNA sequencing and qPCR validation were performed to assess the expression levels of FAM153C-RPL19 in urinary exosomes from PCa patients (n = 826), non-PCa individuals (n = 352), benign prostatic hyperplasia (BPH) patients (n = 396), and healthy controls (n = 428). Receiver operating characteristic (ROC) analysis was conducted to compare the diagnostic performance of FAM153C-RPL19 with PSA and PCA3. FAM153C-RPL19 levels were significantly higher in urinary exosomes of PCa patients than in healthy, BPH, and non-PCa controls. Higher levels correlated with advanced stages (Stage III-IV) and Gleason scores (GS ≥ 7). Urinary exosomal FAM153C-RPL19 outperformed plasma exosomes as a diagnostic marker. It showed superior diagnostic accuracy (AUC = 0.93) over PSA (AUC = 0.81), especially in PSA gray-zone cases (AUC = 0.92). Higher levels were associated with poor prognosis (HR = 2.95, 95 % CI: 1.90-4.58). Combining FAM153C-RPL19 with PSA and PCA3 improved diagnostic performance (AUC = 0.97). These findings suggest that urinary exosomal FAM153C-RPL19 is a promising noninvasive biomarker for prostate cancer detection and risk stratification, with higher specificity and sensitivity than PSA, particularly in the diagnostic gray zone. Its strong correlation with disease progression and prognosis further supports its potential clinical utility in liquid biopsy-based PCa screening.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsBiomarkers, TumorExosomesHumansMalePrognosisAgedMiddle AgedChinaProstatic HyperplasiaROC CurveProstate-Specific AntigenCase-Control StudiesEast Asian People

Stichwörter der Autor:innen

BiomarkerChimeric RNAFAM153C-RPL19Prostate cancerUrinary exosomes

Substanzen

Biomarkers, TumorProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China; Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, 510120, China. Electronic address:…
  • Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China.
  • Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China; Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
  • Department of Urology, Peking University People's Hospital, Beijing, 100044, China.
  • Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, 510120, China.
  • Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China; Southern Medical University, Guangzhou, 510120, China.

Förderung

  • Special Project for Research and Development in Key areas of Guangdong Province
  • National Natural Science Foundation of China
  • Southern Medical University
  • China Postdoctoral Science Foundation
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Key Technologies Research and Development Program of Guangzhou Municipality

Zitieren

APA

Cheng, B., Luo, T., Wu, Y., Hu, J., Yang, C., Wu, J., Luo, Y., Shangguan, W., Li, W., Yang, L., Huang, W., Ma, C., Li, Z., Sun, B., Wang, Q., Xu, K., Wu, P., & Huang, H. (2025). Urinary exosomal FAM153C-RPL19 chimeric RNA as a diagnostic and prognostic biomarker for prostate cancer in Chinese patients. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217938

Vancouver

Cheng B, Luo T, Wu Y, Hu J, Yang C, Wu J, et al. Urinary exosomal FAM153C-RPL19 chimeric RNA as a diagnostic and prognostic biomarker for prostate cancer in Chinese patients. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217938

BibTeX
@article{Cheng2025,
  author = {Cheng, Bisheng and Luo, Tianlong and Wu, Yongxin and Hu, Jintao and Yang, Chenwei and Wu, Jilin and Luo, Yong and Shangguan, WenTai and Li, Weijia and Yang, Lin and Huang, Wenxue and Ma, Cunzhen and Li, Zhuohang and Sun, Boyuan and Wang, Qiong and Xu, KeWei and Wu, Peng and Huang, Hai},
  title = {Urinary exosomal FAM153C-RPL19 chimeric RNA as a diagnostic and prognostic biomarker for prostate cancer in Chinese patients},
  journal = {Cancer Letters},
  year = {2025},
  doi = {10.1016/j.canlet.2025.217938}
}
Kostenlos starten →